BRPI0815008B8 - vacinas multiméricas com múltiplos epítopos contra influenza - Google Patents

vacinas multiméricas com múltiplos epítopos contra influenza

Info

Publication number
BRPI0815008B8
BRPI0815008B8 BRPI0815008A BRPI0815008A BRPI0815008B8 BR PI0815008 B8 BRPI0815008 B8 BR PI0815008B8 BR PI0815008 A BRPI0815008 A BR PI0815008A BR PI0815008 A BRPI0815008 A BR PI0815008A BR PI0815008 B8 BRPI0815008 B8 BR PI0815008B8
Authority
BR
Brazil
Prior art keywords
multiple epitopes
multimeric
influenza vaccines
multimeric influenza
vaccines
Prior art date
Application number
BRPI0815008A
Other languages
English (en)
Inventor
Ben-Yedidia Tamar
Singer Yossi
Original Assignee
Biondvax Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondvax Pharmaceuticals Ltd filed Critical Biondvax Pharmaceuticals Ltd
Publication of BRPI0815008B1 publication Critical patent/BRPI0815008B1/pt
Publication of BRPI0815008B8 publication Critical patent/BRPI0815008B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

vacinas multiméricas com múltiplos epítopo contra influenza. a presente invenção se refere a vacinas multiméricas baseadas em peptídeos com múltiplos epítopos. em particular, a presente invenção se refere ao uso de vacinas multiméricas baseadas em peptídeo com múltiplos epítopos que estimulam imunidade protetora contra influenza.
BRPI0815008A 2007-08-02 2008-08-03 vacinas multiméricas com múltiplos epítopos contra influenza BRPI0815008B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95349807P 2007-08-02 2007-08-02
PCT/IL2008/001062 WO2009016639A2 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines

Publications (2)

Publication Number Publication Date
BRPI0815008B1 BRPI0815008B1 (pt) 2019-11-19
BRPI0815008B8 true BRPI0815008B8 (pt) 2021-05-25

Family

ID=40305020

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815008A BRPI0815008B8 (pt) 2007-08-02 2008-08-03 vacinas multiméricas com múltiplos epítopos contra influenza

Country Status (18)

Country Link
US (2) US8747861B2 (pt)
EP (1) EP2173376B1 (pt)
JP (1) JP5654345B2 (pt)
KR (1) KR101580660B1 (pt)
CN (1) CN101795709B (pt)
AU (1) AU2008281384C1 (pt)
BR (1) BRPI0815008B8 (pt)
CA (1) CA2695399C (pt)
DK (1) DK2173376T3 (pt)
EA (1) EA017887B1 (pt)
ES (1) ES2539818T3 (pt)
HK (1) HK1142809A1 (pt)
HR (1) HRP20150479T1 (pt)
HU (1) HUE025149T2 (pt)
MX (1) MX2010001284A (pt)
PL (1) PL2173376T3 (pt)
PT (1) PT2173376E (pt)
WO (1) WO2009016639A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
JP2011519828A (ja) 2008-04-18 2011-07-14 バクシネート コーポレーション フラジェリンの欠失変異体と使用方法
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5805195B2 (ja) 2010-08-23 2015-11-04 カンステム バイオテック カンパニー リミテッド Ｎｏｄ２アゴニストで処理した幹細胞またはその培養物を含む免疫疾患および炎症性疾患の予防および治療用の薬学的組成物
EP2678361A4 (en) * 2011-02-21 2015-06-03 Vaxinnate Corp COMPOSITIONS WITH IMPROVED IMMUNOGENICITY AND / OR REDUCED REACTIVITY AND METHOD OF USE THEREOF
CA2828068C (en) * 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
AU2012273039B2 (en) * 2011-06-20 2016-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
ES2490915B1 (es) * 2011-09-12 2015-09-17 Laboratorios Del Dr. Esteve, S.A. Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos
CA3207612A1 (en) * 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US20150056231A1 (en) * 2012-04-02 2015-02-26 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
CN103055311B (zh) * 2012-12-28 2014-05-21 中山大学 一种传染性喉气管炎粘膜疫苗及其制备方法和应用
EP2943221A1 (en) * 2013-01-10 2015-11-18 Novartis AG Influenza virus immunogenic compositions and uses thereof
EP3125931A4 (en) * 2014-04-03 2017-09-20 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
RU2769406C2 (ru) * 2016-02-03 2022-03-31 СиДжи ДИСКАВЕРИ, ИНК. Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
WO2018126060A1 (en) 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US20220118077A1 (en) * 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
CA3167318A1 (en) * 2020-02-14 2021-08-19 Neil P. King Polypeptides, compositions, and their use to treat or limit development of an infection
US20230364261A1 (en) * 2020-09-21 2023-11-16 Sri International Targeted antigen delivery system and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) * 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9201139D0 (en) 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
PL170980B1 (pl) * 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
AU5128493A (en) * 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Recombinant multivalent m protein vaccine
US5683695A (en) * 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) * 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5977081A (en) * 1997-05-20 1999-11-02 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
ES2298316T3 (es) * 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9807805D0 (en) 1998-04-09 1998-06-10 Smithkline Beecham Biolog Vaccine
CN1306438A (zh) 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
CA2337754C (en) * 1998-08-21 2011-05-24 Altaf A. Lal Recombinant multivalent malarial vaccine against plasmodium falciparum
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP2003509465A (ja) 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
WO2001024810A1 (en) 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
BRPI0111830B8 (pt) 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
EP1603590A4 (en) 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
US7108679B2 (en) * 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
CA2589556A1 (en) * 2004-12-16 2006-08-03 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
NZ556004A (en) 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
KR20080027777A (ko) * 2005-06-01 2008-03-28 배리에이션 바이오테크놀로지스 아이엔씨. 펩티드­기초 인플루엔자 백신 제제
US7260958B2 (en) * 2005-09-14 2007-08-28 National Taipei University Technology Electrohydrodynamic condenser device
EP1945253A2 (en) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
AU2006322907B2 (en) * 2005-12-06 2012-08-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
AU2007300663A1 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
JP2010536878A (ja) 2007-08-21 2010-12-02 ダイナバックス テクノロジーズ コーポレイション インフルエンザタンパク質を製造および使用する組成物および方法

Also Published As

Publication number Publication date
CN101795709B (zh) 2013-07-17
US8747861B2 (en) 2014-06-10
WO2009016639A2 (en) 2009-02-05
JP2010535026A (ja) 2010-11-18
EP2173376B1 (en) 2015-03-25
HRP20150479T1 (hr) 2015-07-17
AU2008281384A1 (en) 2009-02-05
HK1142809A1 (en) 2010-12-17
PL2173376T3 (pl) 2015-08-31
CA2695399C (en) 2017-10-17
PT2173376E (pt) 2015-07-30
CN101795709A (zh) 2010-08-04
EA017887B1 (ru) 2013-03-29
WO2009016639A3 (en) 2009-04-30
AU2008281384B2 (en) 2012-02-16
MX2010001284A (es) 2010-08-31
EP2173376A2 (en) 2010-04-14
KR101580660B1 (ko) 2015-12-28
EA201070219A1 (ru) 2010-08-30
JP5654345B2 (ja) 2015-01-14
ES2539818T3 (es) 2015-07-06
US20110182974A1 (en) 2011-07-28
DK2173376T3 (en) 2015-06-29
BRPI0815008B1 (pt) 2019-11-19
CA2695399A1 (en) 2009-02-05
US9353159B2 (en) 2016-05-31
US20140286982A1 (en) 2014-09-25
HUE025149T2 (hu) 2016-01-28
KR20100045473A (ko) 2010-05-03
AU2008281384C1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
BRPI0815008B8 (pt) vacinas multiméricas com múltiplos epítopos contra influenza
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
BR112018000601A2 (pt) moléculas de anticorpo que se ligam ao cd22
BRPI0813527A2 (pt) Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
TWD161587S (zh) 袋子的固定構件
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
AU333673S (en) Bar chair
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
CO6331298A2 (es) Vacunas contra coccidiosis
BRPI0921359A2 (pt) Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos
CA2798214C (en) Vaccine against beta-herpesvirus infection and use thereof
BRPI0821240B8 (pt) formas mutantes de estreptolisina o
BR112015004515A2 (pt) composição imunogênica
DOP2014000140A (es) Preparaciones que comprenden emodépsido amorfo
AR084541A1 (es) PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA
CY1123049T1 (el) Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο για χρηση σε ανθρωπους
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
UY33208A (es) Composiciones que comprenden productos de azúcar cisteína
BR112014002426A2 (pt) ventilador axial, um rotor de ventilador
BRPI0817230A2 (pt) vacina contra influenza inativada, e, uso da vacina
UY33789A (es) Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab
DK2175881T3 (da) Intradermal influenzavaccine
GB201106162D0 (en) Combination vaccine
MX345739B (es) Nuevo adyuvante.
BR112016008569A8 (pt) glicerol, uso não terapêutico de glicerol, uso de glicerol, método não terapêutico para o condicionamento do couro cabeludo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2734 DE 30-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.